AlphaQuest LLC Increases Stock Holdings in Inogen, Inc $INGN

Key Points

• AlphaQuest LLC significantly increased its stake in Inogen, Inc by 924.4% in the first quarter, holding approximately 0.18% of the company with a total of 48,289 shares valued at $344,000.
• Inogen reported earnings of ($0.15) per share for the last quarter, surpassing analysts' expectations, and generated revenue of $92.28 million, exceeding the consensus estimate of $90.40 million.
• The stock has an average rating of "Moderate Buy" with a consensus price target of $11.00, despite different analysts setting varied target prices in recent reports.

AlphaQuest LLC grew its holdings in shares of Inogen, Inc (NASDAQ:INGN - Free Report) by 924.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 48,289 shares of the medical technology company's stock after purchasing an additional 43,575 shares during the quarter. AlphaQuest LLC owned approximately 0.18% of Inogen worth $344,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Wells Fargo & Company MN grew its position in Inogen by 27.8% during the fourth quarter. Wells Fargo & Company MN now owns 13,917 shares of the medical technology company's stock valued at $128,000 after buying an additional 3,031 shares during the period. Invesco Ltd. boosted its stake in Inogen by 2.0% in the fourth quarter. Invesco Ltd. now owns 78,142 shares of the medical technology company's stock valued at $717,000 after acquiring an additional 1,545 shares during the last quarter. Barclays PLC grew its position in shares of Inogen by 18.6% during the 4th quarter. Barclays PLC now owns 65,826 shares of the medical technology company's stock valued at $604,000 after acquiring an additional 10,318 shares during the period. Marshall Wace LLP bought a new position in shares of Inogen during the 4th quarter valued at approximately $234,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Inogen by 25.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company's stock worth $5,574,000 after purchasing an additional 123,208 shares during the last quarter. 89.94% of the stock is currently owned by institutional investors.

Inogen Stock Performance

Inogen stock traded up $0.11 during mid-day trading on Tuesday, reaching $8.10. The company's stock had a trading volume of 215,237 shares, compared to its average volume of 245,709. The firm's fifty day moving average price is $7.09 and its two-hundred day moving average price is $7.15. Inogen, Inc has a 12-month low of $5.70 and a 12-month high of $12.91. The company has a market capitalization of $219.02 million, a P/E ratio of -7.64 and a beta of 1.78.

Inogen (NASDAQ:INGN - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical technology company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. Inogen had a negative return on equity of 13.77% and a negative net margin of 7.58%.The firm had revenue of $92.28 million for the quarter, compared to the consensus estimate of $90.40 million. Inogen has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, research analysts predict that Inogen, Inc will post -1.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on INGN shares. Stifel Nicolaus dropped their price objective on Inogen from $10.00 to $7.00 and set a "hold" rating on the stock in a research note on Thursday, May 8th. B. Riley initiated coverage on Inogen in a research note on Monday, June 16th. They issued a "buy" rating and a $14.00 target price on the stock. Finally, Needham & Company LLC raised Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 price target on the stock in a research report on Thursday, May 22nd. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $11.00.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.